Medication Use Evaluation (MUE) for Continuous Heparin Infusions in Hospitalized Patients
1 other identifier
observational
100
1 country
1
Brief Summary
Unfractionated heparin (UFH) is an anticoagulant to prevent thrombus formation or worsening of an existing thrombus. It is indicated for patients with deep vein thrombosis/pulmonary embolism (DVT/PE) or acute coronary syndrome (ACS). Unfractionated heparin treatment consists of an initial bolus followed by a continuous infusion that is adjusted based on the patient's subsequent partial thromboplastin time (PTT) levels
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 31, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 21, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
August 21, 2023
CompletedFirst Submitted
Initial submission to the registry
October 17, 2023
CompletedFirst Posted
Study publicly available on registry
October 23, 2023
CompletedMarch 24, 2026
September 1, 2022
10 months
October 17, 2023
March 20, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Incidents of deviations from protocol
Appropriate anticoagulation management will be measured using Percent time in therapeutic range based on aPTT levels
30 Days
Eligibility Criteria
• Patient's aged 18 years or older with a confirmed diagnosis of DVT/PE based on imaging or a confirmed diagnosis of ACS requiring heparin therapy
You may qualify if:
- Patient's aged 18 years or older with a confirmed diagnosis of DVT/PE based on imaging or a confirmed diagnosis of ACS requiring heparin therapy
You may not qualify if:
- History of bleeding in the last 30 days
- History of HIT
- Use of systemic anticoagulants for another indication
- Presence of coagulation disorder prior to admission (i.e. hemophilia, sickle cell anemia, etc.)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Methodist Richardson Medical Center
Dallas, Texas, 75082, United States
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 17, 2023
First Posted
October 23, 2023
Study Start
October 31, 2022
Primary Completion
August 21, 2023
Study Completion
August 21, 2023
Last Updated
March 24, 2026
Record last verified: 2022-09